Lars Fruergaard Jørgensen, currently head of corporate development at Novo Nordisk A/S, will become chief executive on 1 January 2017, succeeding Lars Rebien Sørensen, who is retiring. Mr Sorenson has worked at the Danish company for 34 years, spending the last 16 as CEO. During this period, he oversaw the company’s expansion into a global producer of diabetes drugs. Following the changeover, Mr Sørensen will be nominated as a director of the Novo Nordisk Foundation and Novo A/S, the foundation’s holding company.
The CEO-designate, Mr Jørgensen, joined Novo Nordisk in 1991 and held jobs outside Denmark before advancing to the position of executive vice president.
The Danish company also announced that Jakob Riis, currently head of operations for China and the Pacific region, has become head of North American operations.
Copyright 2016 Evernow Publishing Ltd